ABSTRACT Zika virus (ZIKV) is a major public health concern due to its overwhelming spread into the Americas. Currently, there are neither licensed vaccines nor antiviral therapies available for the treatment of ZIKV. We aimed to identify and rationally optimize effective therapeutic regimens for ZIKV by evaluating the antiviral potentials of the approved broad-spectrum antiviral agents favipiravir (FAV), interferon alpha (IFN), and ribavirin (RBV) as single agents and in combinations. For these studies, Vero cells were infected with ZIKV in the presence of increasing concentrations of FAV, IFN, or/and RBV for 4 days. Supernatants were harvested daily, and the viral burden was quantified by a plaque assay on Vero cells. The time course of the viral burden during treatment in vitro was characterized by a novel translational, mechanism-based model, which was subsequently used to rationally optimize combination dosage regimens. The combination regimen of FAV plus IFN provided the greatest extent of viral inhibition without cytotoxicity, reducing the viral burden by 4.4 log 10 PFU/ml at concentrations of 250 M FAV and 100 IU/ml IFN. Importantly, these concentrations are achievable in humans. The translational, mechanism-based model yielded unbiased and reasonably precise curve fits. Simulations with the model predicted that clinically relevant regimens of FAV plus IFN would markedly reduce viral burdens in humans, resulting in at least a 10,000-fold reduction in the amount of the virus during the first 4 days of treatment. These findings highlight the substantial promise of rationally optimized combination dosage regimens of FAV plus IFN, which should be further investigated to combat ZIKV.
Z
ika virus (ZIKV), a mosquito-borne flavivirus, emerged in the Western Hemisphere in 2015 and has since spread explosively throughout the Americas. Serious and long-term health consequences have been associated with infection during recent outbreaks; this applies especially during pregnancy, where devastating birth defects such as microcephaly, brain damage, and fetal loss have been reported (1, 2) . Neurological complications have also been linked to ZIKV infection in adults, including Guillain-Barre syndrome and acute disseminated encephalomyelitis (3, 4) .
Currently, there are neither approved vaccines nor any antiviral therapies for the prevention or treatment of ZIKV infections. This lack of available medical countermeasures represents a major challenge in the response to (re)emerging viral infections. Traditionally, available antiviral agents are often used as a first line of defense against (re)emerging viruses to decelerate the spread of infection in a population, thereby providing time for the development of new vaccine candidates or new drugs (5) . Since antiviral agents specific for ZIKV do not exist, other therapeutic approaches must be investigated. A promising and tangible strategy is to evaluate the antiviral potential of drugs that are currently approved for other indications (i.e., drug repurposing). As repurposed agents have been extensively studied in humans, detailed information regarding pharmacokinetics (PK), pharmacology, and safety is readily available. Compared to traditional drug development, repurposing can tremendously expedite the clinical availability of novel treatment regimens against ZIKV.
Agents that are active against multiple viruses seem particularly suitable candidates for repurposing as anti-ZIKV therapies. Favipiravir (FAV) (formerly T-705), ribavirin (RBV), and interferon alpha (IFN) are three broad-spectrum antiviral agents that are currently approved for the treatment of other viral diseases. FAV is a polymerase inhibitor that is licensed in Japan to treat influenza, but it has also demonstrated activity against Ebola virus, West Nile virus, and yellow fever virus (6) (7) (8) . RBV and IFN are effective against a multitude of different RNA and DNA viruses and are currently approved by the Food and Drug Administration as combination therapy for the treatment of hepatitis C virus.
Here, we aimed to evaluate the antiviral activities of FAV, RBV, and IFN as single agents and in two-drug combinations against ZIKV to identify potential therapeutic regimens that will maximize virus suppression. As a second objective, we aimed to characterize the time course of the viral burden for these agents as monotherapies and combination therapies via a novel, translational, mechanism-based mathematical model (MBM). This MBM was subsequently used to rationally optimize clinically relevant combination dosage regimens that accounted for the plasma concentration-time profiles of these antiviral agents in humans. Overall, this translational approach was used to identify, design, and rationally optimize novel antiviral combination dosage regimens that are safe and effective in patients infected with ZIKV.
RESULTS

Antiviral monotherapy evaluations.
The antiviral activities of FAV, IFN, and RBV were evaluated against a human ZIKV isolate in vitro. As monotherapy, FAV suppressed the production of infectious ZIKV in a dose-dependent manner, and suppression was sustained for the entire duration of the experiment (Fig. 1A) . FAV was particularly effective at concentrations of 250 and 500 M, which delayed virus production by approximately 1 day and reduced peak viral titers by 2.1 log 10 PFU/ml and 3.6 log 10 PFU/ml, respectively (Fig. 1A) . The 50% effective concentration (EC 50 ) estimate (based on a Hill model) for FAV against ZIKV over the 4-day experiment was 316.6 M (49.74 g/ml).
IFN also displayed activity against ZIKV but only at concentrations of Ͼ100 IU/ml (Fig. 1C) . ZIKV inhibition (INH) was transient in the regimens utilizing 100 IU/ml and 1,000 IU/ml, as the viral burden increased steadily in these arms and eventually attained peak titers that were similar to that of the control by day 4 posttreatment. Continued suppression was achieved at 10,000 IU/ml of IFN, which inhibited the viral burden by approximately 2. log 10 PFU/ml (Fig. 1C) . IFN exhibited an EC 50 of 407.8 IU/ml for ZIKV over 4 days of treatment.
The antiviral activity of RBV against ZIKV was limited. RBV concentrations that were Յ10 g/ml were ineffective and failed to suppress the production of infectious virus (Fig. 1B) . Substantial virus inhibition was observed at concentrations of 100 g/ml and 1,000 g/ml; however, inhibition was not sustainable, and the viral burden continued to increase in both experimental arms throughout the 4-day experiment. Viral titers in the 100-g/ml arm were similar to those for the control after 4 days of treatment, while the 1,000-g/ml regimen further delayed ZIKV replication. The overall EC 50 for RBV against ZIKV was 121.7 g/ml. Importantly, RBV exhibited strong cytostatic effects at 1,000 g/ml and was slightly cytostatic at 100 g/ml (data not shown), which may explain some of the antiviral activity at these concentrations. Toxicity in uninfected control cells was not observed with FAV or IFN treatment at the highest concentrations evaluated in these studies.
Antiviral evaluations with combination therapy.
We evaluated all possible twodrug combinations of FAV, RBV, and IFN against ZIKV. The combination of FAV and IFN provided substantial virus inhibition, and the degree of inhibition on day 3 was higher than that of either agent as monotherapy ( Fig. 1D and G) . Moreover, complete virus suppression was observed with 250 M FAV plus 10,000 IU/ml of IFN as well as 500 M FAV combined with 1,000 IU/ml or 10,000 IU/ml of IFN. FAV and RBV did not enhance antiviral activity when administered together, as the addition of RBV to FAV yielded viral titers that were similar to those with FAV alone for most regimens ( Fig. 1E and H) . Importantly, increasing concentrations of RBV decreased virus suppression in regimens containing 500 M FAV ( Fig. 1E and H) . The viral burden was lower in experimental arms receiving 1,000 g/ml of RBV; however, this finding is attributed to RBV-related cytotoxicity. Finally, the effectiveness of RBV plus IFN was higher than that of singleagent therapy but only when high RBV concentrations (Ն100 g/ml) were present ( Fig.  1F and I ). Regimens containing Յ10 g/ml RBV yielded virus inhibition profiles similar to those observed for IFN monotherapy.
Mechanism-based pharmacodynamic modeling. We developed a novel pharmacodynamic (PD) MBM to describe the relationship between concentrations of FAV, RBV, and IFN as monotherapy and in combination and the production of infectious ZIKV over The infectious virus burden, reported as log 10 PFU per milliliter, was quantified from cell culture supernatants by a plaque assay on Vero cells. The data are representative of results from one experiment. Data points represent the mean observed viral burdens for three independent samples, and error bars correspond to one standard deviation from three independent samples. Lines through the data points signify the predicted viral burden as determined by the mathematical model. The dashed horizontal line represents the assay limit of detection of 100 PFU/ml.
time. In addition to the antiviral effects of FAV, RBV, and IFN, the MBM (Fig. 2) contained the cytotoxic effects associated with RBV treatment. An antagonistic interaction between FAV and RBV was further required to describe the data (Fig. 1H ). The model simultaneously described the viral burdens for all single-agent regimens and two-drug combinations well, as illustrated by the model predictions (depicted as solid lines in Fig.  1A to F). Curve fits were unbiased and precise, with linear regression analysis of fitted-versus-observed plots for viral burdens yielding correlation coefficient (r) values of 0.96 for individual fits and 0.94 for population fits (Fig. 3) . The values for the maximum extent of inhibition (I max ) for ZIKV production were estimated to be 1.00 for IFN and 0.9999 for FAV, indicating complete or near-complete suppression (Table 1 ). In contrast, the I max was markedly lower (0.954) for RBV, suggesting that even very high RBV concentrations could not achieve complete virus inhibition. The 50% inhibitory concentration (IC 50 ) estimates were 41.7 M for FAV, 7.86 g/ml for RBV, and 4.12 IU/ml for IFN. It should be noted that the model IC 50 estimates refer to the suppression of the release of infectious ZIKV from the final intracellular virus compartment and that these estimates are different from the EC 50 s (based on an empirical Hill model) reported above. The EC 50 instead correlates the drug concentration to the overall viral burden quantified by the plaque assay.
The substantial inhibition of virus production by the combination of FAV and IFN was well described by the MBM; excitingly, the viral burden was decreased by approximately 4.5 log 10 units relative to the no-treatment controls at 250 M FAV with 100 IU/ml of IFN. More importantly, the exposures associated with these concentrations are clinically achievable (9, 10) . Extensive virus suppression was also observed with RBV in combination with IFN but only when high levels of RBV were present (Ն100 g/ml). Since the estimated 50% cytotoxicity concentration (SC 50_RBV ) for RBV was 150 g/ml (Table 1) , the effectiveness of this regimen was attributed mainly to the considerable cytotoxicity associated with RBV treatment. In contrast, FAV and RBV in combination demonstrated less-than-additive interactions for an antiviral effect. The estimated interaction factor was 1.37 (Table 1) , which indicated antagonism (P Ͻ 0.001 [likelihood ratio test] in comparison to a model without an interaction factor). Antagonism was most apparent with FAV at 500 M and RBV at 100 g/ml ( Fig. 1E and H) .
Predictive performance. The normalized prediction distribution error (NPDE) is well known to be a statistically rigorous method to assess predictive performance. This plot suggested a good predictive performance of the proposed final model, with approximately 95% of markers falling symmetrically within the ideal range of Ϫ2 to ϩ2 for standard normally distributed variables (Fig. 4) . This suggested a suitable predictive performance of the proposed model for subsequent use in simulations. a I max was assumed to be normally distributed on a logistically transformed scale (I maxTransformed ). The population mean value of I max is reported on a normal scale (i.e., from 0 to 1), whereas the between-curve variability is presented as the standard deviation of a normal distribution on a logistically transformed scale. b Between-curve variability was included and required in this population PD model to account for minor biological differences between experimental curves on separate days. The uncertainty (percent standard error) for the estimated between-curve variability tended to be large for some parameters. However, this has only a minor or no effect on the predictive performance of the model, as shown by the NPDE. c CV, coefficient of variation. d SYNANT, synergy or antagonism.
Simulations of combination therapy with FAV and IFN against ZIKV. Our results suggested that FAV in combination with IFN was the most promising regimen for the treatment of ZIKV. Based on our translational MBM, antiviral activity against ZIKV for combination therapy with FAV and IFN was predicted for clinically relevant dosage regimens. Human PK profiles associated with clinically relevant regimens of FAV administered orally were evaluated in combination with a standard clinical regimen of injected IFN at 36 million IU/ml twice daily (9) (Fig. 5A and B) . PK profiles were corrected for protein binding, and only free-drug concentrations were used in the simulations. Two FAV regimens that have been used clinically were evaluated in this study: (i) the standard regimen used for the treatment of human influenza virus infections in phase 3 clinical trials in the United States (1,800 mg at 0 and 12 h on day 1, followed by 800 mg every 12 h starting at 24 h), which we termed the low-dose regimen (ClinicalTrials registration number NCT02008344), and (ii) a clinical regimen that was used to treat Ebola virus-infected patients during the 2014 outbreak (2,400 mg at 0 h, 2,400 mg at 8 h, and 1,800 mg at 16 h on day 1, followed by 1,200 mg every 12 h starting at 24 h), referred to as the high-dose regimen (11) . We also assessed a third FAV regimen that employed doses that were between those of the low-and high-dose regimens (1,800 mg at 0, 8, and 16 h on day 1, followed by 900 mg every 12 h starting at 24 h). This treatment was designated the middle-dose regimen (Fig. 5B) .
In the absence of treatment, our simulations showed that the ZIKV burden achieved peak viral titers of 8 log 10 PFU/ml (Fig. 5C and D) . As monotherapy, FAV decreased peak ZIKV titers relative to the control by 1.2 log 10 units for the low-dose regimen, 1.5 log 10 units for the middle-dose regimen, and 1.9 log 10 units for the high-dose regimen (Fig.  5C ). FAV treatment also delayed the achievement of peak viral titers by approximately 3 days. IFN as monotherapy delayed ZIKV production but was unable to suppress viral replication, as peak viral titers were similar to those of the control by day 5 (Fig. 5C) .
Simulations with all combination treatment regimens yielded substantial virus suppression relative to monotherapy, and the degree of suppression occurred in a dose-dependent manner (Fig. 5D ). All regimens markedly inhibited the ZIKV burden relative to the control, especially at the earlier time points; however, the viral burden increased only slowly over the course of the 10-day simulation, indicating that these regimens were effective at delaying ZIKV production (Fig. 5D) . After 10 days of treatment, the model predicted that the low-dose regimen in combination with IFN would inhibit the viral burden by 2.1 log 10 PFU/ml, the middle-dose regimen would decrease the viral load by 3.1 log 10 PFU/ml, and the high-dose regimen would decrease the viral load by 4.2 log 10 PFU/ml.
DISCUSSION
The rapid spread of ZIKV throughout the Americas coupled with the serious neurologic symptoms associated with this disease underscore the urgent need to identify effective medical countermeasures against ZIKV. Although vaccination is traditionally a cornerstone for the prevention of viral diseases, recent studies have called into question the safety of an anti-ZIKV vaccine due to concerns of antibody-dependent enhancement; the latter may exacerbate infections caused by other flaviviruses (i.e., dengue virus) (12) . This is a significant shortcoming, since multiple flaviviruses cocirculate geographically and are transmitted by the same mosquito vector (13) . Consequently, optimal antiviral therapy will play a significant role in the management of ZIKV infections. Antiviral agents specific for ZIKV do not currently exist. Here, we applied a drug-repurposing strategy to identify effective therapeutic regimens for ZIKV by evaluating approved agents that have broad-spectrum antiviral activity. In addition to single-agent evaluations, compounds were also assessed in combination to maximize viral suppression. Finally, we developed a novel MBM to predict the effectiveness of . The low-dose regimen refers to the standard FAV regimen used to treat human influenza virus infections, which is in phase 3 clinical trials in the United States. The high-dose regimen corresponds to the FAV regimen employed to treat humans infected with Ebola virus. The middle-dose regimen was selected because it employs drug levels that were between the low-and high-dose regimens. (C) ZIKV burden resulting from treatment with the high-, medium-, and low-FAV regimens or the IFN regimen as monotherapy. (D) ZIKV burden during treatment with regimens of IFN plus FAV, as predicted by the mechanism-based mathematical model. The dashed horizontal line at y ϭ 2 log 10 units corresponds to the limit of detection of the plaque assay that was used to quantify viral burdens in the experimental assays.
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Antimicrobial Agents and Chemotherapy clinically relevant antiviral regimens when human PK profiles associated with these regimens are simulated. Our experimental assays and MBM showed that antiviral treatment with two compounds yielded superior virologic outcomes compared to those with single-agent therapy. When FAV was combined with IFN, this combination demonstrated substantial ZIKV suppression without exhibiting cytotoxicity to uninfected host cells. More importantly, considerable antiviral effectiveness was observed at clinically relevant FAV and IFN concentrations. These findings strongly support the further investigation of FAV and IFN as a combination treatment against ZIKV.
The addition of IFN to RBV also enhanced antiviral activity, resulting in extensive virus suppression compared to monotherapy. However, suppression occurred only with regimens that contained high levels of RBV, which are not achievable in humans due to toxicity, thereby limiting the potential clinical utility of this treatment regimen. The combination of FAV and RBV demonstrated statistically significant antagonism using a competitive-interaction model as the null reference model (14) . We hypothesize that these antagonistic interactions for virus suppression stem from the potential overlap in the mechanism(s) of action between FAV and RBV, as both of these compounds may act as purine analogs to inhibit viral replication (15) (16) (17) . Antagonism was most obvious when 500 M FAV was combined with 100 g/ml of RBV; the latter was the highest concentration of RBV that did not yield extensive cytotoxicity. We postulate that at these concentrations, RBV was outcompeting FAV for utilization by the ZIKV RNAdependent RNA polymerase during viral replication. Since RBV has substantially lower virus inhibition than FAV (I max value of 0.954 for RBV, compared to 0.9999 for FAV), the overall degree of ZIKV suppression by RBV was limited. Thus, these findings demonstrate that FAV in combination with RBV is not an optimal regimen to pursue for the treatment of human ZIKV infections.
Our experimental assays were conducted by using static concentrations of each compound. In humans, plasma concentration-time profiles for agents are dynamic after administration according to each drug's PK. We conducted simulations with our novel MBM using clinically relevant PK profiles for FAV and IFN in combination to predict the antiviral effectiveness of various regimens against ZIKV in humans. Our simulations showed that all combination regimens substantially inhibited ZIKV production over a 10-day period. The maximum extent of virus inhibition was achieved when the highdose FAV regimen that was used to treat Ebola virus-infected patients was combined with the standard clinical dose of IFN, suppressing the viral burden by over 15,000-fold. It is important to note that our studies and analyses do not account for the human immune response. Therefore, our findings may underpredict antiviral activity, and additional suppression may be achieved in the presence of a functioning immune system. The implications for this are significant, as the antiviral effectiveness provided by the clinical regimen of IFN plus a low-dose FAV regimen may be sufficient to allow the immune system to clear the remaining infection; this low-dose FAV regimen was used in influenza virus clinical trials (ClinicalTrials registration number NCT02008344).
Despite the promising antiviral activity of the combination treatment of IFN and FAV, there are weaknesses associated with this therapeutic regimen. First, FAV has demonstrated teratogenic and embryotoxic effects in many different animal models, including monkeys (18); thus, FAV is contraindicated for pregnant women and cannot be utilized for protection against microcephaly or other birth defects associated with ZIKV infection during pregnancy. Additionally, the ability of FAV to penetrate into the central nervous system of humans is unknown, and others have shown that IFN does not efficiently cross the blood-brain barrier (19) . This suggests that FAV plus IFN may not protect against the neurologic disease resulting from ZIKV in adults. However, antiviral intervention with FAV and IFN has the potential to control ZIKV in peripheral tissues, which may in turn prevent or decrease the severity of neurologic consequences occurring with infection. FAV is detected in semen (18) , a site where ZIKV has been shown to persist for many months (20, 21) . There is also evidence that systemic IFN penetrates into seminal fluid (22) . Therefore, FAV plus IFN may be effective at control-ling ZIKV infection in human sexual organs and, as a result, help to prevent sexual transmission of the virus to uninfected partners.
There are several limitations to our study. First, the available information regarding human PK for FAV was sparse (10). Our PK simulations were based on mean concentration profiles for healthy volunteers. Although these PK data allowed us to simulate the average exposure in humans, we could not include between-patient variability since population PK models for FAV and IFN were not available. Also, the PK in patients with ZIKV may differ from those in healthy volunteers. As more information becomes accessible, we will be able to more accurately simulate FAV PK profiles and account for between-patient variability in a population. Second, our evaluations relied on FAV concentrations and not the concentrations of the active intracellular triphosphorylated moiety. We are currently investigating the intracellular phosphorylation kinetics of FAV in different host cells and will incorporate these findings into a future MBM. Finally, our evaluations were conducted on a single ZIKV isolate. Although the isolate that we employed represents a contemporary human ZIKV isolate, future experiments will focus on assessing antiviral combination regimens against multiple strains of ZIKV in different host cell lines.
In conclusion, our study demonstrated that clinically relevant FAV and IFN combination regimens have great potential as a treatment strategy for ZIKV infections. These encouraging findings suggest that further preclinical studies (including animal models) and, ultimately, clinical investigations of the combination of FAV plus IFN are warranted.
MATERIALS AND METHODS
Cells and compounds. Vero cells (ATCC CCL-81, American Type Culture Collection, Manassas, VA) were cultured in Eagle's minimum essential medium (MEM) (Cellgro; Corning, Manassas, VA) in the presence of 5% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO) and a 1% penicillin-streptomycin solution (HyClone, Logan City, UT) at 37°C in 5% CO 2 . Cells were passaged twice weekly via trypsin digestion to maintain subconfluent cell monolayers.
FAV, RBV, and IFN were purchased from commercial vendors. FAV was obtained from Cellagen Technology (San Diego, CA), RBV was obtained from Tokyo Chemical Industry (Portland, OR), and IFN was obtained from PBL Assay Science (Piscataway, NJ). All three compounds were stored according to the manufacturers' recommendations.
Virus. The 2015 human ZIKV Puerto Rican strain PRVABC59 was acquired from BEI Resources (Manassas, VA). Virus stocks were generated by passing the ZIKV isolate on Vero cells. Cell supernatants were collected 3 days after infection and clarified by high-speed centrifugation. The virus was aliquoted and frozen at Ϫ80°C in the presence of 20% FBS. Stock viral titers were determined by a plaque assay on Vero cells.
ZIKV plaque assay. Supernatant samples were thawed at 37°C and then stored on ice. Samples were diluted serially 10-fold in MEM containing 2% FBS, and a 100-l aliquot of each dilution was then added to confluent Vero cell monolayers in 6-well plates. The virus was allowed to attach to cells for 1 h at 37°C in 5% CO 2 . After the 1-h incubation period, 3 ml of a primary MEM agar overlay containing a final concentration of 0.6% agar and 5% FBS was added to all wells. A second MEM agar overlay supplemented with a final concentration of 1% agar, 1% FBS, 200 g/ml of DEAE-dextran, and 0.008% neutral red was added to each well 3 days later. Plaques were counted 24 h after the addition of the second agar overlay. The viral burden is reported as PFU per milliliter.
Antiviral evaluations. The antiviral activities of FAV, IFN, and RBV against ZIKV were evaluated on Vero cells in triplicate, as previously described (23), with the exception that ZIKV was inoculated onto confluent Vero cell monolayers at a multiplicity of infection of 0.01 PFU/cell. FAV was evaluated at concentrations ranging from 0 M to 500 M, RBV was evaluated at concentrations ranging from 0 g/ml to 1,000 g/ml, and IFN was evaluated at concentrations ranging from 0 IU/ml to 10,000 IU/ml. For single-agent evaluations, cell supernatants were harvested daily, clarified by high-speed centrifugation, and frozen at Ϫ80°C until the end of the experiment. The infectious virus burdens for all samples were quantified simultaneously by a plaque assay on Vero cells. The EC 50 value for each compound was determined over the entire time course of the study by using GraphPad Prism software (La Jolla, CA). Briefly, the area under the viral burden-time curve (AUC viral_burden ) was calculated for all treatment regimens (Fig. 1A to C) , and an inhibitory sigmoid-E max model was fit to the AUC viral_burden values. Each assay was conducted in triplicate.
Combination assays were performed with FAV, IFN, and RBV by using a 6-by-6 checkerboard format in which 5 concentrations of each drug with a no-treatment control were assessed alone and as all possible combinations of concentrations, resulting in 36 assay points. Each assay was conducted in triplicate. Supernatants were harvested on day 3 posttreatment, as peak viral burdens were achieved at this time point in all previous time course analyses. Samples were processed as described above and quantified for infectious virus by a plaque assay.
Mechanism-based pharmacodynamic mathematical model. A new MBM was developed to investigate the inhibitory effects of FAV, RBV, and IFN as monotherapy as well as of all 2-drug combinations of these compounds on viral replication. The virus and cells were exposure to a range of concentrations of the above-mentioned three drugs. The model contained compartments for uninfected and infected host cells as well as extracellular and intracellular virus.
Host cell dynamics. Uninfected host cells (U) were infected by extracellular virus (V extra ) via a second-order process with the infection rate constant k infect . IFN inhibited the infection. In our in vitro experiments, uninfected and infected (I) host cells were assumed not to replicate. Infected host cells died via a first-order process (death rate constant k death ), which was stimulated by a minor cytotoxic effect of FAV at high concentrations. Cytotoxicity by RBV affected both uninfected and infected host cells. The differential equations for U and I were
The initial condition (IC) was set to the targeted inoculum of 10 6.3 cells/ml for total uninfected host cells and estimated for infected host cells. The cytotoxicity (k cytotox ) by RBV is described below. Viral replication. After host cells were infected, new intracellular virus (V i1 ) was generated with a first-order synthesis rate constant (k syn ). Based on our previously developed mechanism-based model, a series of five transit compartments for intracellular virus (V i1 , V i2 , V i3 , V i4 , and V i5 , linked by transit rate constant k tr ) was used to describe virus maturation and replication (24) . Differential equations for intracellular virus were as follows (initial conditions of V i1 to V i5 all zero):
The death of infected host cells caused a loss of the associated immature intracellular virus. Therefore, cytotoxicity by RBV, for example, caused the death of infected host cells and the loss of intracellular virus as described by k death in the differential equations for V i1 to V i5 .
Extracellular virus (V extra ) arose from the egress of intracellular virus from compartment V i5 and was subject to a first-order loss rate constant (k loss, V extra ). At the initiation of our in vitro experiment, all extracellular virus was assumed to rapidly infect host cell, and thus, the initial condition for V extra was set to zero. 
